|Category:||Medical & Pharma|
|Organizer:||Parenteral Drug Association (PDA)|
Dear users, due to the COVID-19 epidemic, PDA Europe - Advanced Therapy Medicinal Products 2021 may have been postponed or canceled, please visit the official website to check the latest information.
Overview interest facts - PDA Europe - Advanced Therapy Medicinal Products 2021
PDA Europe - Advanced Therapy Medicinal Products 2021, the rise of tissue engineering at the turn of the century led health authorities around the world to consider the need for specific legislation to clarify how they would be regulated. The EU first defined cell and gene therapy products as medicines in 2003, but did not specifically address tissue engineering. This perceived gap was filled through Regulation 1394/2007 which defined tissue engineering by function not structure and required all ATMPs to be approved by the European Medicines Agency.